Researchers at Charles River have developed a series of small molecules that target the ATM kinase and have shown promise for the treatment of Huntington’s disease in preclinical studies
Here is a description of your company. Proin ex id consectetur lobortis. Aliquam, velit vel faucibus dapibus, augue justo ullamcorper turpis, nec convallis metus nunc vel turpis.
